Please assess the completion status of the following clinical trial:

Trial Title: Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 - 70 years of age~* Histologic diagnosis of IgA nephropathy~* Proteinuria \> 1 g/day or UPC \> 1 mg/mg or 113 mg/mmol at least twice~* Receiving treatment with the maximum dose of ARB for at least 3 months~* Patients who are willing to give written, informed consent~Exclusion Criteria:~* eGFR \< 15 ml/min/1.73 sq.m~* UPC \>5000 mg/g or 570 mg/mmol, or \<500 mg/g or 57 mg/mmol~* Serum K+ \> 5.2 mmol/L~* Presence of bilateral renal artery stenosis~* Presence of diabetes mellitus~* Renal histology showing pathologies other than IgAN~* Known allergy to ARB or DRI~* Patients on ARB/ACEi combination within 12 weeks of randomization~* Concurrent treatment with corticosteroids, Nsaid, or immunosuppressant~* Patients with connective tissue disease or obstructive uropathy~* Patients with malignancy or conditions severely limiting life expectancy~* Female who are pregnant or intending to conceive~* Female of child-bearing age unwilling to practice contraception~* Patients who are unable to give informed consent~* Patients simultaneously participating in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).